Rapid Ebola Test Validated in Field Trials
|
By LabMedica International staff writers Posted on 15 Jul 2015 |
At present, diagnosis of Ebolavirus disease requires transport of venipuncture blood to field biocontainment laboratories for testing by real-time reverse transcription polymerase chain reaction (RT-PCR), resulting in delays that complicate patient care and infection control efforts.
However, RT-PCR is a slow and complex test that comes with attached risks for the health care workers responsible for the collection, transportation and testing of the blood. The complexity and slow turnaround for this diagnostic have been blamed for delaying success in containing the Ebola epidemic.
An international team led by those at the Boston Children's Hospital (MA. USA) performed a rapid diagnostic test on fingerstick blood samples from 106 individuals with suspected Ebolavirus disease presenting at two clinical centers in Sierra Leone during February 2015. They compared the point-of-care rapid diagnostic test results with clinical real-time RT-PCR results (RealStar Filovirus Screen RT-PCR kit 1·0; altona Diagnostics GmbH; Hamburg, Germany) for venipuncture plasma samples tested in a Public Health England field reference laboratory.
The team also performed the rapid diagnostic ReEBOV Antigen Rapid Test (Corgenix; Broomfield, CO, USA), on whole blood and real-time RT-PCR on plasma, on 284 specimens in the reference laboratory, which were submitted to the laboratory for testing from many clinical sites in Sierra Leone. In point-of-care testing, all 28 patients who tested positive for Ebolavirus disease by RT-PCR were also positive by fingerstick rapid diagnostic test and 71 of 77 patients who tested negative by RT-PCR were also negative by the rapid diagnostic test. In laboratory testing, all 45 specimens that tested positive by RT-PCR were also positive by the rapid diagnostic test, and 214 of 232 specimens that tested negative by RT-PCR were also negative by the rapid diagnostic test.
The authors concluded that the ReEBOV rapid diagnostic test had 100% sensitivity and 92% specificity in both point-of-care and reference laboratory testing in this population. With two independent readers, the test detected all patients who were positive for Ebolavirus by altona real-time RT-PCR; however, this benchmark itself had imperfect sensitivity. The study was published on June 26, 2015, in the journal the Lancet.
Related Links:
Boston Children's Hospital
altona Diagnostics GmbH
Corgenix
However, RT-PCR is a slow and complex test that comes with attached risks for the health care workers responsible for the collection, transportation and testing of the blood. The complexity and slow turnaround for this diagnostic have been blamed for delaying success in containing the Ebola epidemic.
An international team led by those at the Boston Children's Hospital (MA. USA) performed a rapid diagnostic test on fingerstick blood samples from 106 individuals with suspected Ebolavirus disease presenting at two clinical centers in Sierra Leone during February 2015. They compared the point-of-care rapid diagnostic test results with clinical real-time RT-PCR results (RealStar Filovirus Screen RT-PCR kit 1·0; altona Diagnostics GmbH; Hamburg, Germany) for venipuncture plasma samples tested in a Public Health England field reference laboratory.
The team also performed the rapid diagnostic ReEBOV Antigen Rapid Test (Corgenix; Broomfield, CO, USA), on whole blood and real-time RT-PCR on plasma, on 284 specimens in the reference laboratory, which were submitted to the laboratory for testing from many clinical sites in Sierra Leone. In point-of-care testing, all 28 patients who tested positive for Ebolavirus disease by RT-PCR were also positive by fingerstick rapid diagnostic test and 71 of 77 patients who tested negative by RT-PCR were also negative by the rapid diagnostic test. In laboratory testing, all 45 specimens that tested positive by RT-PCR were also positive by the rapid diagnostic test, and 214 of 232 specimens that tested negative by RT-PCR were also negative by the rapid diagnostic test.
The authors concluded that the ReEBOV rapid diagnostic test had 100% sensitivity and 92% specificity in both point-of-care and reference laboratory testing in this population. With two independent readers, the test detected all patients who were positive for Ebolavirus by altona real-time RT-PCR; however, this benchmark itself had imperfect sensitivity. The study was published on June 26, 2015, in the journal the Lancet.
Related Links:
Boston Children's Hospital
altona Diagnostics GmbH
Corgenix
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Microbiology News
- Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea
- Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
- Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
- Oral and Lung Microbiome Changes Linked to Severe Long Covid Symptoms
- Study Finds Distinct Malaria Parasites Linked to Sickle Cell Trait Protection
- Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis
- Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification
- Genomic Workflow Identifies Fungal Pathogens Before Blood Cultures Turn Positive
- FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample
- One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
- FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
- New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
- Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories
- Study Finds Frequent Overlap in Antibodies to Lyme and Other Tick-Borne Pathogens
- Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk
- FDA Breakthrough-Designated Urine Panel Aims to Shorten Pathogen and Susceptibility Testing
Channels
Clinical Chemistry
view channel
Blood Proteins Linked to Mortality Risk and Biological Aging Across Organ Systems
Older adults of the same chronological age can differ markedly in health, chronic disease burden, and resilience. Biological age aims to capture these differences by reflecting how rapidly the body and... Read more
Two-Step Blood Test Improves Specificity for Alzheimer’s Diagnosis
Early Alzheimer’s disease can be difficult to identify before more severe cognitive symptoms emerge. Blood tests measuring phosphorylated tau protein p-tau217 may help detect disease-related changes, but... Read moreMolecular Diagnostics
view channel
Tumor and Immune Biomarkers Linked to Treatment Response in T-Cell Lymphoma
T-follicular helper cell lymphoma (TFHL) is a subtype of peripheral T-cell lymphoma associated with poor prognosis and limited treatment options after relapse. Its molecular abnormalities include frequent... Read more
Blood MRD Testing Aids Risk Analysis in Bladder and Other Cancers
Natera (Austin, TX, USA) presented findings from 25 abstracts, including nine oral presentations, at the ESMO Congress 2026 in Madrid. The research examined circulating tumor DNA (ctDNA) testing for molecular... Read moreHematology
view channel
Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification
Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read moreImmunology
view channel
Prototype Point-of-Care Lateral Flow Test Aims to Improve Neonatal Sepsis Triage
Sepsis in newborns and young infants remains a major clinical challenge, particularly in low- and middle-income countries. An estimated 2.3 million newborns die each year, with sepsis contributing substantially... Read more
Immune and Inflammatory Markers May Help Assess CAR T-Cell Complication Risk
Cytokine release syndrome (CRS) can occur after chimeric antigen receptor (CAR) T-cell therapy in patients with autoimmune disease. Identifying which patients are more likely to develop this complication... Read morePathology
view channel
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Roche Launches Automated Test to Support Mesothelioma Differential Diagnosis
Mesothelioma is a rare, deadly cancer that forms in the tissue lining many internal organs. Most patients are diagnosed late, with median overall survival reported at 12 to 18 months. Differential diagnosis... Read more
Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
In hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, accurate recurrence-risk assessment helps guide treatment decisions. However, individual risks... Read more
AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
High-grade serous tubo-ovarian carcinoma is an aggressive cancer arising in the ovaries or fallopian tubes. Some tumors exhibit homologous recombination deficiency (HRD), a feature reflecting impaired DNA repair.... Read moreTechnology
view channel
Microfluidic Assay Predicts Treatment Response in Pediatric Leukemia
Acute lymphoblastic leukemia (ALL) is a rapidly developing blood cancer that can disrupt production of mature infection-fighting white blood cells within months. More than 120,000 people in the U.... Read more
AI Models Use Routine Blood Tests and Health Records to Predict Cancer Risk
Cancer screening programs cover only certain cancers and often rely on broad eligibility criteria, limiting individualized risk assessment across multiple cancer types. Routine health data, including blood... Read moreIndustry
view channel
CE-Marked IVD Sequencing Platform Launches Across Ten EU Countries
Clinical laboratories using sequencing in regulated diagnostic workflows need systems that support clearly defined processes and documentation. In Europe, meeting applicable EU IVDR requirements also means... Read more








